BNGO insider transaction filings
Bionano Genomics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-09. Screen BNGO transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings by 1 insider — 8,000 shares, $9,705 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
- Largest priced transaction: purchase of 4,000 shares @ $1.22 ($4,860) by Luderer Albert, filed 2026-08-21.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Luderer Albert — Interim Chief Executive, Director | 2 | 2 legs · 8,000 sh · $9,705 | — | — |
| Adamchak Mark — Principal Accounting Officer | 1 | — | — | 1 |
| Dixon Jonathan V. — General Counsel | 1 | — | — | 1 |
| Hastie Alex Reid — Chief Scientific Officer | 1 | — | — | 1 |
| OLDAKOWSKI MARK — Chief Operating Officer | 1 | — | — | 1 |
Recent Form 4 filings — Bionano Genomics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Luderer Albert — Interim Chief Executive, Director | Purchase (P): 4,000 @ $1.21 | EDGAR |
| 2026-08-21 | 4 | Luderer Albert — Interim Chief Executive, Director | Purchase (P): 4,000 @ $1.22 | EDGAR |
| 2026-08-05 | 4 | Hastie Alex Reid — Chief Scientific Officer | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | OLDAKOWSKI MARK — Chief Operating Officer | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Dixon Jonathan V. — General Counsel | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Adamchak Mark — Principal Accounting Officer | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Adamchak Mark — Principal Accounting Officer | Tax withholding (F): 7 @ $1.30 | EDGAR |
| 2026-06-03 | 4 | Dixon Jonathan V. — GENERAL COUNSEL | Tax withholding (F): 24 @ $1.30 | EDGAR |
| 2026-06-03 | 4 | Chaubey Alka — CHIEF MEDICAL OFFICER | Tax withholding (F): 24 @ $1.30 | EDGAR |
| 2026-06-03 | 4 | OLDAKOWSKI MARK — CHIEF OPERATING OFFICER | Tax withholding (F): 27 @ $1.30 | EDGAR |
| 2026-05-14 | 4 | Rajkovic Aleksandar — Director | Grant/award (A): 9,149 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Linney Yvonne — Director | Grant/award (A): 9,149 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Vuori Kristiina MD — Director | Grant/award (A): 9,149 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | TWOMEY CHRISTOPHER J — Director | Grant/award (A): 9,149 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | BARKER DAVID L — Director | Grant/award (A): 9,149 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Adamchak Mark — Principal Accounting Officer | Tax withholding (F): 3 @ $1.10 | EDGAR |
| 2026-02-18 | 4 | Dixon Jonathan V. — GENERAL COUNSEL | Tax withholding (F): 6 @ $1.10 | EDGAR |
| 2026-02-18 | 4 | Chaubey Alka — CHIEF MEDICAL OFFICER | Tax withholding (F): 18 @ $1.10 | EDGAR |
| 2026-02-18 | 4 | OLDAKOWSKI MARK — CHIEF OPERATING OFFICER | Tax withholding (F): 20 @ $1.10 | EDGAR |
| 2026-02-18 | 4 | Holmlin R. Erik — PRESIDENT AND CEO, Director | Tax withholding (F): 51 @ $1.10 | EDGAR |
| 2026-02-04 | 4 | Adamchak Mark — Principal Accounting Officer | Grant/award (A): 10,890 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Dixon Jonathan V. — GENERAL COUNSEL | Grant/award (A): 26,117 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Chaubey Alka — CHIEF MEDICAL OFFICER | Grant/award (A): 27,737 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | OLDAKOWSKI MARK — CHIEF OPERATING OFFICER | Grant/award (A): 27,737 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Holmlin R. Erik — PRESIDENT AND CEO, Director | Grant/award (A): 69,484 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Chaubey Alka — Chief Medical Officer | Tax withholding (F): 51 @ $4.06 | EDGAR |
| 2025-09-12 | 4 | OLDAKOWSKI MARK — Chief Operating Officer | Tax withholding (F): 59 @ $4.06 | EDGAR |
| 2025-09-12 | 4/A | OLDAKOWSKI MARK — Chief Operating Officer | Tax withholding (F): 59 @ $4.06 | EDGAR |
| 2025-06-12 | 4 | Vuori Kristiina MD — Director | Grant/award (A): 2,775 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Linney Yvonne — Director | Grant/award (A): 2,775 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Luderer Albert — Director | Grant/award (A): 2,775 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Mamuszka Hannah — Director | Grant/award (A): 2,775 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Rajkovic Aleksandar — Director | Grant/award (A): 2,775 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | TWOMEY CHRISTOPHER J — Director | Grant/award (A): 2,775 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | BARKER DAVID L — Director | Grant/award (A): 2,775 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | OLDAKOWSKI MARK — Chief Operating Officer | Tax withholding (F): 27 @ $3.69 | EDGAR |
| 2025-06-03 | 4 | Adamchak Mark — Principal Accounting Officer | Tax withholding (F): 7 @ $3.69 | EDGAR |
| 2025-06-03 | 4 | Chaubey Alka — Chief Medical Officer | Tax withholding (F): 24 @ $3.69 | EDGAR |
| 2025-06-03 | 4 | Holmlin R. Erik — President and CEO, Director | Tax withholding (F): 75 @ $3.69 | EDGAR |
| 2025-06-03 | 4 | Dixon Jonathan V. — General Counsel | Tax withholding (F): 25 @ $3.69 | EDGAR |
| 2025-03-18 | 4 | Dixon Jonathan V. — General Counsel | Grant/award (A): 6,559 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Adamchak Mark — Principal Accounting Officer | Grant/award (A): 3,029 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Holmlin R. Erik — President and CEO, Director | Tax withholding (F): 198 @ $3.47 · Grant/award (A): 17,449 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | OLDAKOWSKI MARK — Chief Operating Officer | Grant/award (A): 6,966 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Chaubey Alka — Chief Medical Officer | Grant/award (A): 6,966 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | OLDAKOWSKI MARK — Chief Operating Officer | Tax withholding (F): 20 @ $5.73 | EDGAR |
| 2025-02-19 | 4 | Dixon Jonathan V. — General Counsel | Tax withholding (F): 6 @ $5.73 | EDGAR |
| 2025-02-19 | 4 | Holmlin R. Erik — President and CEO, Director | Tax withholding (F): 51 @ $5.73 | EDGAR |
| 2025-02-19 | 4 | Chaubey Alka — Chief Medical Officer | Tax withholding (F): 18 @ $5.73 | EDGAR |
| 2025-02-19 | 4 | Adamchak Mark — Principal Accounting Officer | Tax withholding (F): 4 @ $5.73 | EDGAR |
Recent 8-K events — Bionano Genomics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BNGO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →